Antiviral selection in the management of acute retinal necrosis
Patrick MK Tam1, Claire Y Hooper2, Susan Lightman21Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, N.T., Hong Kong, People’s Republic of China; 2Institute of Ophthalmology, Moorfields Eye Hospital, London, UKAbstract: Ther...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ecc0359f028f4f4882d0ef23935058b5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Patrick MK Tam1, Claire Y Hooper2, Susan Lightman21Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, N.T., Hong Kong, People’s Republic of China; 2Institute of Ophthalmology, Moorfields Eye Hospital, London, UKAbstract: There is no consensus on the optimal antiviral regimen in the management of acute retinal necrosis, a disease caused by herpetic viruses with devastating consequences for the eye. The current gold standard is based on retrospective case series. Because the incidence of disease is low, few well-designed, randomized trials have evaluated treatment dosage and duration. Newer oral antiviral agents are emerging as alternatives to high-dose intravenous acyclovir, avoiding the need for inpatient intravenous treatment. Drug resistance is uncommon but may also be difficult to identify. Antiviral drugs have few side effects, but special attention needs to be paid to patients who have underlying renal disease, are pregnant or are immunocompromised.Keywords: acute retinal necrosis, acyclovir, herpes, retinitis |
|---|